Zymeworks 10-Q Details $173.7M Q3 Profit, $560M Theravance Deal Accounting
ZYME sits 93% above its 52-week low of $16.003.
Summary
Zymeworks' Q3 10-Q shows $256.5M of revenue and $173.7M of net income on the $250M Jazz milestone, plus the full accounting for the $560.4M Theravance deal funded with $600M of non-recourse debt.
Key Events · Earnings and Guidance · ZYME
-
Q3 Swing to $173.7M Profit
Total revenue was $256.5M versus $27.6M a year earlier, including the $250.0M Jazz milestone earned on Ziihera's U.S. first-line GEA approval; net income was $173.7M, or $2.28 per diluted share.
-
Theravance Deal Accounting Booked
Net consideration paid was $560.4M, allocated to $415.4M of YUPELRI product rights, $96.7M TRELEGY milestone receivable and $104.4M goodwill; Theravance contributed only about $1.5M of revenue for the seven post-closing days.
-
$600M Non-Recourse Financing Stack
A $250M Royalty Pharma loan (9.7% effective rate, $258.2M net liability) is secured by 30% of Ziihera royalties, and $350M of 8.25% OMERS notes ($338.9M carrying) are serviced by 75% of YUPELRI profit-share cash flows; interest expense on these liabilities was $6.7M in the quarter.
-
Dissenters Open Cayman Appraisal
Certain former Theravance holders commenced a statutory appraisal action on October 23, 2026; Zymeworks booked $26.3M of deferred consideration at the $17.00 per share deal price, with the ultimate amount still subject to the proceeding.
Analysis · ZYME · Life Sciences
This 10-Q is where the balance sheet actually changed shape, after the 8-K this morning gave only headline numbers. Zymeworks closed the $560.4M net Theravance acquisition on September 23, 2026, booking $415.4M of YUPELRI product rights and $104.4M of goodwill, and funded it with $600M of non-recourse paper: a $250M Royalty Pharma loan against 30% of Ziihera royalties and $350M of 8.25% OMERS notes secured by 75% of YUPELRI profit-share cash flows. That structure is why the company can report a $173.7M quarterly profit and still say it has no plans for equity issuance. The offsetting items are real: interest expense on the sale-of-future-revenue liabilities was $6.7M in the quarter, and dissenting Theravance holders opened a Cayman appraisal action on October 23, 2026, with $26.3M of deferred consideration booked at the $17.00 deal price and the final amount still open.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZYME was trading at $30.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $16.00 to $31.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.